Navigation Links
A genetic accelerator hits the gas on autoimmune diseases
Date:1/16/2012

A "genetic accelerator" is responsible for the most severe cases of Lupus (systemic lupus erythemathosus), an autoimmune disease: the accelerator, called enhancer HS1.2, speeds up the activity of some critical genes of the immune system involved in the disease.

A team of Italian researchers at the Catholic University of Sacred Heart in Rome found that the enhancer HS1.2 is like the accelerator of the car and boosts the pathological immune response typical of the disease by enhancing the production of the pathological antibodies that attack the patient's body instead of defending it (autoantibodies).

Professor Gianfranco Ferraccioli, Head of the Rheumatology Unit of Rheumatology and Internal Medicine of the Catholic University led the research in collaboration with Professor Domenico Frezza at Tor Vergata University of Rome and Professor Raffaella Scorza at University of Milan and they published their results in the Annals of the Rheumatic Diseases.

The discovery could lead to more targeted and effective therapies against this complex disease, in particular against the most severe cases, Professor Ferraccioli explained.

Systemic lupus erythematosus is an autoimmune disease, that is a condition in which the patient's immune system goes haywire and begins to attack the body rather than defend it. Lupus affects about 60,000 people in Italy, with a major prevalence among females. Lupus affects so several different organs and tissues and causes a variety of symptoms, including joint pain, fever, skin rashes, hair loss, Raynaud's disease, anemia, nephritis.

The therapies currently used are based on cortisone, anti-malarial drugs and immunosuppressants (azathioprine, mycophenolate, cyclophosphamide) and biologic drugs (rituximab, Belimumab).

But in many cases Lupus is more aggressive and so far the origin of this particular severity was quite unclear.

Italian researchers discovered that the cause of the most severe cases is the accelerator HS1.2 enhancer. Enhancers are DNA sequences that accelerate the activation of neighboring genes and enhance their functioning, hence the name.

HS1.2 leads to enhanced activation of the "transcription factor NF-KB" (a transcription factor is a molecule that "reads" the genes to make them work), which in turn dramatically increases the aggressiveness of the inflammatory processes underlying the disease.

Italian researchers have discovered that over 30 per cent of the patients has the enhancer HS1.2 in their Dna and that it causes a more severe form of Lupus.

The researchers reached this finding after demonstrating that the enhancer HS1.2 promotes also other autoimmune diseases such as rheumatoid arthritis and identified how the enhancer causes increased susceptibility to autoimmune diseases.

"Our results suggest that new drugs that turn off the enhancer HS1.2, or inhibit its effect on NF-KB, can stop the disease without the need for immunosuppressive drugs or other therapies with many side effects," Ferraccioli said. "Moreover the discovery of the role of this enhancer allows us to better classify patients and formulate a precise prognosis for each one moving toward more personalized care."


'/>"/>

Contact: Gianfranco Ferraccioli
gf.ferraccioli@rm.unicatt.it
39-347-322-4547
Catholic University of Rome
Source:Eurekalert

Related medicine news :

1. UNC scientists collaborate to find first major genetic mutation associated with hereditary prostate cancer risk
2. TGen researchers map potential genetic origins, pathways of lung cancer in nonsmokers
3. Genetic predisposition to disease common in 2 supercentenarians: New study
4. Doubt Cast on Use of Genetic Test Before Plavix
5. Analysis does not support genetic test before use of anti-clotting drug
6. Key genetic error found in family of blood cancers
7. Researchers describe a new genetic program that converts static cells into mobile invasive cells
8. Autism Speaks Autism Genetic Resource Exchange joins NIH National Database for Autism Research
9. Study probes genetic link to sickle cell pain management
10. Unique genetic marker may improve detection of recurrent ovarian cancer
11. Scientists identify strategies to conquer lifestyle and genetic factors related to chronic diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , ... January 17, 2017 , ... A prescription medication ... of the fourth Cradle to Cradle Product Design Challenge , the Cradle ... a series of six circular design challenges scheduled to run through early 2018. The ...
(Date:1/17/2017)... ... January 17, 2017 , ... Wettstein ... to families and business professionals throughout central Colorado, is joining local nonprofit Aurora ... The Aurora Warms The Night organization is committed to breaking the cycle of ...
(Date:1/17/2017)... ... January 17, 2017 , ... Seceon , the ... in real-time, today announced a strategic partnership with TechLab Security, a ... Seceon partners, TechLab Security has become a strategic partner and a value added ...
(Date:1/17/2017)... New York, NY (PRWEB) , ... January 17, ... ... of Inc. Magazine’s fastest-growing private companies and ranked among the top US security ... first Board of Directors. This announcement brings a year-long independent board nomination ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... the Montclair State University’s Athletic Training Education program forged a relationship built upon ... Education Program, which is consists of both student members and certified members ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... GRAND RAPIDS, Mich. , Jan. 17, 2017 ... of Richard M. Erwin as Vice ... Catalyst Pharmaceuticals, where he was Executive Director, Clinical Project Management. ... with over 25 years of experience in global ... a string of successful growth-stage clinical operation build-outs ...
(Date:1/17/2017)...  Bayer today announced the appointment of Dr. Carsten ... Americas, comprising the United States , ... . In this role, Dr. Brunn will report to ... of Bayer AG and President of the Pharmaceutical division. ... the pharmaceutical industry and I,m delighted to have him lead ...
(Date:1/16/2017)... 2017 Research and Markets has announced the ... report to their offering. ... Global multiple myeloma drugs market to grow at a ... report covers the present scenario and the growth prospects of the ... size, the report considers the revenue generated from the sales of ...
Breaking Medicine Technology: